Treatment of Elderly Patients with Higher Risk Myelodysplastic Syndromes with Oral Azacitidine

被引：0
|
作者：
Santini, Valeria [1 ]
Amato, Cristina [1 ]
De Pourcq, Sven [2 ]
della Seta, Roberta [3 ]
Caciagli, Barbara [1 ]
Raddi, Marco Gabriele [1 ]
Consagra, Angela [1 ]
Rigodanza, Luca [1 ]
Mattiuz, Giorgio [2 ]
Defina, Marzia [4 ]
Galimberti, Sara [5 ]
Maestrini, Giacomo [6 ]
Sanna, Alessandro [7 ]
机构：
[1] Univ Florence, MDS Unit, DMSC, AOU Careggi, Florence, Italy
[2] Univ Florence, MDS Unit, DMSC, Florence, Italy
[3] Azienda Osped Toscana Nord Ovest, Hematol, Massa Carrara, Italy
[4] Azienda Osped Univ Senese, Hematol, Siena, Italy
[5] Univ Pisa, Dept Clin & Expt Med, Hematol, Pisa, Italy
[6] AOU Toscana Ctr, Hematol, Florence, Italy
[7] AOU Careggi, Hematol, Florence, Italy
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190016
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia
    Garcia-Manero, Guillermo
    Scott, Bart L.
    Cogle, Christopher R.
    Boyd, Thomas E.
    Kambhampati, Suman
    Hetzer, Joel
    Dong, Qian
    Kumar, Keshava
    Ukrainskyj, Stacey M.
    Beach, C. L.
    Skikne, Barry S.
    LEUKEMIA RESEARCH, 2018, 72 : 79 - 85
  • [42] Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes
    Caocci, G.
    Voso, M. T.
    Angelucci, E.
    Stauder, R.
    Cottone, F.
    Abel, G.
    Nguyen, K.
    Platzbecker, U.
    Beyne-Rauzy, O.
    Gaidano, G.
    Invernizzi, R.
    Molica, S.
    Criscuolo, M.
    Breccia, M.
    Luebbert, M.
    Sanpaolo, G.
    Buccisano, F.
    Ricco, A.
    Palumbo, G. A.
    Niscola, P.
    Zhang, H.
    Fenu, S.
    La Nasa, G.
    Mandelli, F.
    Efficace, F.
    LEUKEMIA RESEARCH, 2015, 39 (08) : 859 - 865
  • [43] Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
    Ritchie, Ellen K.
    CLINICAL INTERVENTIONS IN AGING, 2012, 7 : 165 - 173
  • [44] CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS)-DEFINED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Garcia-Manero, G.
    Savona, M. R.
    Gore, S. D.
    Cogle, C. R.
    Conkling, P.
    Hetzer, J.
    Dong, Q.
    Ukrainskyj, S. M.
    Skikne, B. S.
    LEUKEMIA RESEARCH, 2015, 39 : S50 - S51
  • [45] Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
    Itzykson, Raphael
    Thepot, Sylvain
    Quesnel, Bruno
    Dreyfus, Francois
    Beyne-Rauzy, Odile
    Turlure, Pascal
    Vey, Norbert
    Recher, Christian
    Dartigeas, Caroline
    Legros, Laurence
    Delaunay, Jacques
    Salanoubat, Celia
    Visanica, Sorin
    Stamatoullas, Aspasia
    Isnard, Francoise
    Marfaing-Koka, Anne
    de Botton, Stephane
    Chelghoum, Youcef
    Taksin, Anne-Laure
    Plantier, Isabelle
    Ame, Shanti
    Boehrer, Simone
    Gardin, Claude
    Beach, C. L.
    Ades, Lionel
    Fenaux, Pierre
    BLOOD, 2011, 117 (02) : 403 - 411
  • [46] Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes
    Seymour, John F.
    Bennett, John M.
    List, Alan F.
    Mufti, Ghulam J.
    Gore, Steven D.
    Fenaux, Pierre
    Santini, Valeria
    Hetzer, Joel
    Songer, Stephen
    Skikne, Barry S.
    Beach, Charles L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (01) : 49 - 56
  • [47] Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
    Sallman, David A.
    Al Malki, Monzr M.
    Asch, Adam S.
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel A.
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Komrokji, Rami
    Lancet, Jeffrey
    Kantarjian, Hagop M.
    Gu, Lin
    Zhang, Yajia
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol
    Ramsingh, Giridharan
    Lal, Indu
    Vyas, Paresh
    Daver, Naval G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2815 - +
  • [48] Azacitidine adverse effects in patients with myelodysplastic syndromes
    San Miguel Amigo L.
    Franco Osorio R.
    Mercadal Vilchez S.
    Martínez-Francés A.
    Advances in Therapy, 2011, 28 (Suppl 4) : 6 - 11
  • [49] Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes
    Garcia-Manero, Guillermo
    Gore, Steven D.
    Kambhampati, Suman
    Scott, Bart L.
    Tefferi, Ayalew
    Cogle, Christopher R.
    Edenfield, William
    Hetzer, Joel
    Kumar, Keshava
    Skikne, Barry S.
    BLOOD, 2012, 120 (21)
  • [50] Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
    Cogle, Christopher R.
    Scott, Bart L.
    Boyd, Thomas
    Garcia-Manero, Guillermo
    ONCOLOGIST, 2015, 20 (12): : 1404 - 1412
12345